Skip to main content
Katharine R. Clapham
Rating: 4.9 of 5
( out of 120 reviews )

Katharine R. Clapham, MD

Languages spoken: English

Clinical Locations

Primary Location

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106

University of Utah Hospital

50 N Medical Dr
Salt Lake City , UT 84132
  • Katharine Clapham, MD is an Assistant Professor in the Division of Cardiovascular Medicine. She obtained her A.B. in Biochemical Sciences from Harvard College (2008) and her M.D. from the Health Sciences and Technology joint MIT-Harvard program at Harvard Medical School. Dr. Clapham completed her residency in Internal Medicine at Massachusetts General Hospital in Boston, MA, in 2015, and her fellowship in Cardiovascular Disease at Yale New Haven Hospital in New Haven, CT, in 2018.

    While at Yale, Dr. Clapham developed a keen interest in pulmonary vascular disease during her work in a vascular biology lab. This led her to pursue further training via the Burke Advanced Fellowship in Pulmonary Heart Disease at Brigham and Women's Hospital in Boston, MA, which she successfully completed in 2022.

    Dr. Clapham's clinical and research interests are focused on pulmonary vascular disease, and she currently serves as Co-Director of the Pulmonary Hypertension and Dyspnea Program at the University of Utah.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    Certification Board of Nuclear Cardiology
    National Board of Echocardiography

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 120 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    December 26, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr Clapham was so patient, thorough and helpful. She made sure my issues and concerns were all addressed and outlined a clear way forward to a get-well plan.

    November 20, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Pleasant, knowledgeable and easy to work with.

    November 20, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Very good knowledgeable takes time

    November 12, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Smart, caring and thoughtful.

    November 06, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr. Clapham was extremely courteous and professional. She took an ample amount of time with me as a first-time patient in order to really understand my history and needs. She outlined a plan going forward which met my needs and was exactly what I desired.

    November 04, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    She is an outstanding Cardiologist. She is kind and caring. She takes time to explain my treatment going forward and always answers my questions.

    October 08, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    She is an expert in her field! She has a way to explain your issues with you in a way you can understand! She even got me tissues when I was in tears:-)

    September 04, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Very caring and thorough doctor

    August 28, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Very efficient and professional

  • Katharine Clapham, MD is an Assistant Professor in the Division of Cardiovascular Medicine. She obtained her A.B. in Biochemical Sciences from Harvard College (2008) and her M.D. from the Health Sciences and Technology joint MIT-Harvard program at Harvard Medical School. Dr. Clapham completed her residency in Internal Medicine at Massachusetts General Hospital in Boston, MA, in 2015, and her fellowship in Cardiovascular Disease at Yale New Haven Hospital in New Haven, CT, in 2018.

    While at Yale, Dr. Clapham developed a keen interest in pulmonary vascular disease during her work in a vascular biology lab. This led her to pursue further training via the Burke Advanced Fellowship in Pulmonary Heart Disease at Brigham and Women's Hospital in Boston, MA, which she successfully completed in 2022.

    Dr. Clapham's clinical and research interests are focused on pulmonary vascular disease, and she currently serves as Co-Director of the Pulmonary Hypertension and Dyspnea Program at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Radiology & Imaging Sciences -Adjunct Assistant Professor
    Academic Divisions Cardiovascular Medicine
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    Certification Board of Nuclear Cardiology
    National Board of Echocardiography

    Education history

    Fellowship Pulmonary Vascular Disease - Brigham and Women's Hospital Clinical Fellow
    Fellowship Pulmonary Hypertension - Yale University School of Medicine Postdoctoral Research Fellow
    Fellowship Cardiovascular Medicine - Yale University School of Medicine Fellow
    Residency Internal Medicine - Massachusetts General Hospital Resident
    Internship Internal Medicine - Massachusetts General Hospital Intern
    Professional Medical Medicine - Harvard Medical School M.D.
    Undergraduate Biochemical Sciences - Harvard College A.B.

    Selected Publications

    Journal Article

    1. Deol AK, Ingram D, Dranow E, Clapham KR, Mayeux JD, Ma CL, Hatton ND, Beck EM, Klanderud D, Ryan JJ (2025). Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories. Pulm Circ, 15(4), e70204. (Read full publication)
    2. ONeill E, Lu DY, Ramakrishna S, Ingram D, Kogelschatz B, Ryan JJ, Mayeux J, Ma C, Klanderud D, Beck E, Dranow E, Hatton N, Clapham K (2025). Methamphetamine-Associated Pulmonary Arterial Hypertension Is Associated With Worse Right Ventricular Function Than Idiopathic Pulmonary Arterial Hypertension: A Matched Study. Echocardiography, 42(5), e70180. (Read full publication)
    3. Zon RL, Sekar A, Clapham K, Oren O, Niroula A, Bick AG, Gibson CJ, Griffin G, Uddin MM, Neuberg D, Natarajan P, Ebert BL (2024). JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism. Blood, 144(20), 2149-2154. (Read full publication)
    4. Ingram D, Alamri AK, Penn BA, Mayeux JD, Ma CL, Clapham KR, Abraham AE, Klanderud D, Sadeh B, Beck EM, Hatton ND, Ryan JJ (2022). Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data. Cureus, 14(11), e31764. (Read full publication)
    5. Thibord F, Klarin D, Brody JA, Chen MH, Levin MG, Chasman DI, Goode EL, Hveem K, Teder-Laving M, Martinez-Perez A, Assi D, Daian-Bacq D, Ito K, Natarajan P, Lutsey PL, Nadkarni GN, de Vries PS, Cuellar-Partida G, Wolford BN, Pattee JW, Kooperberg C, Braekkan SK, Li-Gao R, Saut N, Sept C, Germain M, Judy RL, Wiggins KL, Ko D, ODonnell CJ, Taylor KD, Giulianini F, De Andrade M, Nst TH, Boland A, Empana JP, Koyama S, Gilliland T, Do R, Huffman JE, Wang X, Zhou W, Manuel Soria J, Carlos Souto J, Pankratz N, Haessler J, Hindberg K, Rosendaal FR, Turman C, Olaso R, Kember RL, Bartz TM, Lynch JA, Heckbert SR, Armasu SM, Brumpton B, Smadja DM, Jouven X, Komuro I, Clapham KR, Loos RJF, Willer CJ, Sabater-Lleal M, Pankow JS, Reiner AP, Morelli VM, Ridker PM, Vlieg AVH, Deleuze JF, Kraft P, Rader DJ, Global Biobank Meta-Analysis Initiative Estonian Biobank Research Team 23andMe Research Team Biobank Japan CHARGE Hemostasis Working Group, Min Lee K, Psaty BM, Heidi Skogholt A, Emmerich J, Suchon P, Rich SS, Vy HMT, Tang W, Jackson RD, Hansen JB, Morange PE, Kabrhel C, Trgout DA, Damrauer SM, Johnson AD, Smith NL (2022). Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. Circulation, 146(16), 1225-1242. (Read full publication)
    6. Lee HW, Adachi T, Pak B, Park S, Hu X, Choi W, Kowalski PS, Chang CH, Clapham KR, Lee A, Papangeli I, Kim J, Han O, Park J, Anderson DG, Simons M, Jin SW, Chun HJ (2022). BMPR1A Promotes ID2-ZEB1 Interaction to Suppress Excessive Endothelial to Mesenchymal Transition. Cardiovasc Res. (Read full publication)
    7. Odanovic N, Clapham KR, Gul B, Yong CM, Meadows JL, Altin SE (2021). MENTOR study: Matching expectations and needs to optimize relationships in cardiovascular fellowship training. Am Heart J Plus, 4, 100019. (Read full publication)
    8. Clapham KR, Highland KB, Rao Y, Fares WH (2020). Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. Front Cardiovasc Med, 7, 77. (Read full publication)

    Review

    1. Clapham KR, Singh I, Capuano IS, Rajagopal S, Chun HJ (2019). MEF2 and the Right Ventricle: From Development to Disease. [Review]. Front Cardiovasc Med, 6, 29. (Read full publication)

    Case Report

    1. Clapham KR, Bhimani RD, Cooper JP, Stern TA (2014). Isolated shortness of breath in a woman with a history of Hodgkin lymphoma. J Intensive Care Med, 30(4), 226-8. (Read full publication)

    Letter

    1. Clapham KR, Mesbah Uddin M, Honigberg MC, Gilliland T, Ruan Y, Natarajan P (2022). Venous Thromboembolism Polygenic Risk Score Associates With Pulmonary Hypertension in the UK Biobank. [Letter to the editor]. Circ Genom Precis Med, 15(6), e003797. (Read full publication)
    2. Clapham KR, Rao Y, Sahay S, Sauler M, Lee PJ, Psotka MA, Fares WH, Ahmad T (2020). PECAM-1 is Associated WithOutcomes and Response to Treatment in Pulmonary Arterial Hypertension. [Letter to the editor]. Am J Cardiol, 127, 198-199. (Read full publication)

Schedule Online